International Prognostic Index
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
The International Prognostic Index (IPI) is a clinical tool developed by oncologists to aid in predicting the prognosis of patients with aggressive non-Hodgkin's lymphoma. Prior to 1993, when the IPI was developed, the primary consideration in assessing prognosis was the Ann Arbor stage alone, but this was increasingly found to be an inadequate means of predicting survival outcomes, and so other factors were studied.
A retrospective analysis was performed on 2031 patients with aggressive non-Hodgkin's lymphoma, of all ages, treated with a doxorubicin-based chemotherapy regimen such as CHOP between 1982 and 1987.[1] Several patient characteristics were analyzed to determine whether they were associated with differences in survival, and the factors that emerged as significant were, in addition to the Ann Arbor stage: age, elevated serum lactate dehydrogenase (LDH), performance status, and number of extranodal sites of disease.
International Prognostic Index
One point is assigned for each of the following risk factors:
- Age greater than 60 years
- Stage III or IV disease
- Elevated serum LDH
- ECOG/Zubrod performance status of 2, 3, or 4
- More than 1 extranodal site
The sum of the points allotted correlates with the following risk groups:
- Low risk (0-1 points) - 5-year survival of 73%
- Low-intermediate risk (2 points) - 5-year survival of 51%
- High-intermediate risk (3 points) - 5-year survival of 43%
- High risk (4-5 points) - 5-year survival of 26%
Although the IPI has shown itself to be a useful clinical tool, widely used by oncologists and a mainstay of risk stratification in clinical trials for lymphoma, it should be kept in mind that it was developed prior to the use of rituximab, which is now included with anthracycline-based combination chemotherapy as of the standard of care in B-cell lymphomas (the majority of non-Hodgkin's lymphomas). Rituximab has dramatically improved the outcomes of lymphoma patients, and its effect on the prognostic value of the IPI is uncertain.
Follicular Lymphoma International Prognostic Index (FLIPI)
Given the success of the IPI for intermediate grade lymphomas, an effort was undertaken to develop a similar prognostic index for the most common low-grade lymphoma, follicular lymphoma. The prognostic factors that emerged from this were: age, stage, number of lymph node areas involved, serum hemoglobin level, and serum LDH.[2]
One point is assigned for each of the following adverse prognostic factors:
- Age greater than 60 years
- Stage III or IV disease
- Greater than 4 lymph node groups involved
- Serum hemoglobin less than 12 g/dL
- Elevated serum LDH
The sum of the points allotted correlates with the following risk groups:
- Low risk (0-1 points) - 5 and 10-year survivals of 91% and 71%, respectively
- Intermediate risk (2 points) - 5 and 10-year survivals of 78% and 51%, respectively
- High risk (3-5 points) - 5 and 10-year survivals of 53% and 36%, respectively
References
- ↑ A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329(14):987-94
- ↑ Solal-Céligny et al. Follicular lymphoma international prognostic index. Blood 2004;104(5):1258-1265.
See Also
WikiDoc Research Resources for International Prognostic Index | |
|---|---|
| Articles on International Prognostic Index | Most recent articles on International Prognostic Index • Most cited articles on International Prognostic Index • Review articles on International Prognostic Index • Articles on International Prognostic Index in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on International Prognostic Index | Powerpoint slides on International Prognostic Index • Images of International Prognostic Index • Photos of International Prognostic Index • Podcasts & MP3s on International Prognostic Index • Videos on International Prognostic Index |
| Evidence Based Medicine Regarding International Prognostic Index | AND (Cochrane Database Syst Rev[http://worldselectshop.com/?id=9361 Cochrane Collaboration on International Prognostic Index • Bandolier on International Prognostic Index • TRIP on International Prognostic Index |
| Cost Effectiveness of International Prognostic Index | AND (Cost effectiveness) |
| group5 = Clinical Trials Involving International Prognostic Index | list5 = Ongoing Trials on International Prognostic Index at Clinical Trials.gov • Trial results on International Prognostic Index • Clinical Trials on International Prognostic Index at Google
| group6 = Guidelines / Policies / Government Resources (FDA/CDC) Regarding International Prognostic Index
| list6 = US National Guidelines Clearinghouse on International Prognostic Index • NICE Guidance on International Prognostic Index • NHS PRODIGY Guidance • FDA on International Prognostic Index • CDC on International Prognostic Index
| group7 = Textbook Information on International Prognostic Index
| list7 = Books and Textbook Information on International Prognostic Index
| group8 = Pharmacology Resources on International Prognostic Index
| list8 =
AND (Dose)}} Dosing of International Prognostic Index • AND (drug interactions)}} Drug interactions with International Prognostic Index • AND (side effects)}} Side effects of International Prognostic Index • AND (Allergy)}} Allergic reactions to International Prognostic Index • AND (overdose)}} Overdose information on International Prognostic Index • AND (carcinogenicity)}} Carcinogenicity information on International Prognostic Index • AND (pregnancy)}} International Prognostic Index in pregnancy • AND (pharmacokinetics)}} Pharmacokinetics of International Prognostic Index •
| group9 = Genetics, Pharmacogenomics, and Proteinomics of International Prognostic Index
| list9 =
AND (pharmacogenomics)}} Genetics of International Prognostic Index • AND (pharmacogenomics)}} Pharmacogenomics of International Prognostic Index • AND (proteomics)}} Proteomics of International Prognostic Index
| group10 = Newstories on International Prognostic Index
| list10 = International Prognostic Index in the news • Be alerted to news on International Prognostic Index • News trends on International Prognostic Index</small>
| group11 = Commentary on International Prognostic Index
| list11 =
Blogs on International Prognostic Index
| group12 = Patient Resources on International Prognostic Index | list12 = Patient resources on International Prognostic Index • Discussion groups on International Prognostic Index • Patient Handouts on International Prognostic Index • Directions to Hospitals Treating International Prognostic Index • Risk calculators and risk factors for International Prognostic Index
| group13 = Healthcare Provider Resources on International Prognostic Index
| list13 =
Symptoms of International Prognostic Index • Causes & Risk Factors for International Prognostic Index • Diagnostic studies for International Prognostic Index • Treatment of International Prognostic Index
| group14 = Continuing Medical Education (CME) Programs on International Prognostic Index | list14 = CME Programs on International Prognostic Index
| group15 = International Resources on International Prognostic Index | list15 = International Prognostic Index en Espanol • International Prognostic Index en Francais
| group16 = Business Resources on International Prognostic Index | list16 = International Prognostic Index in the Marketplace • Patents on International Prognostic Index
| group17 = Informatics Resources on International Prognostic Index | list17 = List of terms related to International Prognostic Index
}}
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
